Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LFS-1107, a reversible CRM1 inhibitor (Kd: 12.5 pM), selectively targets and eliminates ENKTL cells, offering potential for cancer research applications [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | LFS-1107, a reversible CRM1 inhibitor (Kd: 12.5 pM), selectively targets and eliminates ENKTL cells, offering potential for cancer research applications [1]. |
In vitro | LFS-1107 at concentrations of 4-9$ over 72 hours selectively eradicates ENKTL cells while preserving normal human PBMCs, demonstrating a favorable safety profile within the PBMC cell lineage [1]. |
In vivo | LFS-1107 (10 mg/kg, intraperitoneal injection, once weekly) can ameliorate the symptoms of ENKTL in a xenografted mouse model with SNK6 cells [1]. |
Molecular Weight | 305.38 |
Formula | C12H11N5OS2 |
CAS No. | 1799330-91-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LFS-1107 1799330-91-8 Membrane transporter/Ion channel CRM1 inhibitor inhibit